- Home
- CTO vs PRTA Comparison
CTO vs PRTA Comparison
Compare CTO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | PRTA |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 595.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CTO | PRTA |
|---|---|---|
| Price | $17.78 | $9.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $22.00 | $18.86 |
| AVG Volume (30 Days) | 254.1K | ★ 600.6K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,948,000.00 | $11,786,000.00 |
| Revenue This Year | $20.87 | N/A |
| Revenue Next Year | $4.29 | $819.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.84 | N/A |
| 52 Week Low | $15.07 | $4.32 |
| 52 Week High | $20.88 | $17.66 |
Technical Indicators
Market Signals| Indicator | CTO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 41.90 |
| Support Level | $17.59 | $9.69 |
| Resistance Level | $17.87 | $10.50 |
| Average True Range (ATR) | 0.22 | 0.57 |
| MACD | -0.08 | -0.11 |
| Stochastic Oscillator | 18.04 | 3.48 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.